Compare · ARDX vs ZSAN
ARDX vs ZSAN
Side-by-side comparison of Ardelyx Inc. (ARDX) and Zosano Pharma Corporation (ZSAN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARDX and ZSAN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ARDX is the larger of the two at $941.9M, about 19.0x ZSAN ($49.7M).
- ARDX has hit the wire 16 times in the past 4 weeks while ZSAN has been quiet.
- ARDX has more recent analyst coverage (24 ratings vs 1 for ZSAN).
- Company
- Ardelyx Inc.
- Zosano Pharma Corporation
- Price
- -
- -
- Market cap
- $941.9M
- $49.7M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- 2015
- News (4w)
- 16
- 0
- Recent ratings
- 24
- 1
Ardelyx Inc.
Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program that is in Phase 2 clinical trial for the treatment of patients with hyperkalemia; and RDX020, a small molecule program for the treatment of metabolic acidosis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Fremont, California.
Zosano Pharma Corporation
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.
Latest ARDX
- Chief Financial Officer Hohenleitner Susan sold $6,009 worth of shares (1,558 units at $3.86), decreasing direct ownership by 0.68% to 227,520 units (SEC Form 4) to cover withholding tax
- Officer Reilly Joseph James sold $15,358 worth of shares (3,982 units at $3.86), decreasing direct ownership by 3% to 145,854 units (SEC Form 4) (for tax liability)
- Officer Bishop John E sold $76,174 worth of shares (19,750 units at $3.86), decreasing direct ownership by 6% to 317,095 units (SEC Form 4) to cover taxes
- Chief Human Resources Officer Brady James Parker sold $58,378 worth of shares (15,136 units at $3.86), decreasing direct ownership by 6% to 245,930 units (SEC Form 4) (tax withholding)
- Chief Commercial Officer Foster Eric Duane sold $33,023 worth of shares (8,562 units at $3.86), decreasing direct ownership by 2% to 409,410 units (SEC Form 4) to cover withholding tax
- Chief Business Officer Kelliher Mike sold $29,922 worth of shares (7,758 units at $3.86), decreasing direct ownership by 2% to 349,660 units (SEC Form 4) (tax liability)
- Chief Patient Officer Williams Laura A sold $41,419 worth of shares (10,739 units at $3.86), decreasing direct ownership by 3% to 367,456 units (SEC Form 4) (tax liability)
- President & CEO Raab Michael sold $225,914 worth of shares (58,574 units at $3.86), decreasing direct ownership by 3% to 1,619,792 units (SEC Form 4) (withholding obligation)
- SEC Form 144 filed by Ardelyx Inc.
- SEC Form 144 filed by Ardelyx Inc.
Latest ZSAN
- SEC Form 25-NSE filed by Zosano Pharma Corporation
- 12 Health Care Stocks Moving In Friday's After-Market Session
- SEC Form 4: Matthews Christine sold $58 worth of shares (82 units at $0.71), decreasing direct ownership by 2% to 4,183 units to satisfy withholding obligation
- SEC Form 4: Lo Steven sold $314 worth of shares (442 units at $0.71), decreasing direct ownership by 3% to 13,163 units (withholding obligation)
- 16 Stocks Moving in Tuesday's Pre-Market Session
- 95 Biggest Movers From Yesterday
- 12 Health Care Stocks Moving In Monday's After-Market Session
- 52 Stocks Moving In Monday's Mid-Day Session
- 69 Biggest Movers From Yesterday
- 12 Health Care Stocks Moving In Friday's Intraday Session